Search

Asthma guidelines have recommended to continue treatment with biologics during COVID-19 pandemic. However, continuation of treatment with biologics in patients with SARS-CoV-2 has been little investigated.To assess the safety of biologics in patients with SARS-CoV-2 infection.A pilot, monocentre, prospective study. Patients aged 12 years old and older with severe asthma on treatment with biologics and confirmed SARS-CoV-2 infection were enrolled. Patients were followed-up with periodic calls at different time points up to 3 months to detect any adverse effect and its relationship with biologic treatment according to the Naranjo Adverse Probability Scale (NAPS). Severity of SARS-CoV-2 infection and clinical outcome were also assessed.Overall, we included 21 patients (10 on therapy with omalizumab, 9 with dupilumab and 2 with mepolizumab). Only a patient reported 2 local adverse events. No other adverse event was reported. Twenty out of 21 patients had a mild COVID-19 course and no adverse outcome was observed.we showed that the scheduled dose of the biologic therapy can be administered safely on time in patients with SARS-CoV-2 infection, as the treatment did not result in adverse events or outcomes. This article is protected by copyright. All rights reserved.

Objective To assess post-traumatic stress symptoms (PTSS) in mothers of children over 2 years of leukemia treatment, to identify possible early family and child predictors of this symptomatology and to indicate the temporal trajectory of PTSS. Methods Participants were 76 Italian mothers (mean age = 37.30 years; SD = 6.07) of children receiving treatment for acute lymphoblastic (n = 69) or myeloid (n = 7) leukemia. Mothers had 12.05 years of education (SD = 3.87), and their incomes were average (52.1%), high (26%) and low (21.9%) for Italian norms, never in poverty. The pediatric patients with leukemia were equally distributed by gender with their mean age of 7.10 years (SD = 4.18). Post-traumatic stress symptoms were measured by a 17-item checklist. Scales assessing anxiety, depression, physical (Brief Symptom Inventory 18) and cognitive functioning (Problem Scale), and life evaluation were also used. There were five assessment points: 1 week (T1), 1 month (T2), 6 months (T3), 12 months (T4) and 24 months post-diagnosis (T5). Results The main results indicated moderate presence of clinical PTSS (≥9 symptoms: 24% at T2, 18% at T3, 16% at T4 and 19% at T5) that remained stable across time points, whereas Brief Symptom Inventory 18 Global score decreased and life evaluation improved. A series of hierarchical regression models identified cognitive functioning early after the diagnosis as the best predictive factor of PTSS across time points. Conclusion Specific psychological interventions could be devised for mothers at risk for short and long-term PTSS just after the diagnosis. Copyright © 2012 John Wiley & Sons, Ltd.